PEAK6’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.14M Sell
107,200
-536,500
-83% -$23.1M 0.01% 840
2026
Q1
$23.7M Sell
643,700
-773,300
-55% -$36.6M 0.06% 304
2025
Q4
$72.1M Buy
1,417,000
+139,400
+11% +$7.13M 0.13% 131
2025
Q3
$70.9M Buy
1,277,600
+1,000,400
+361% +$58.6M 0.1% 147
2025
Q2
$19.1M Sell
277,200
-304,400
-52% -$20.7M 0.04% 397
2025
Q1
$40.4M Buy
581,600
+182,500
+46% +$15.1M 0.09% 184
2024
Q4
$34.3M Buy
+399,100
New +$43.2M 0.07% 227

Other funds holding NVO

PEAK6's NVO Position: Q2 2026 in Review

PEAK6 sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 156,695 shares — an estimated $6.73M sold.

PEAK6 first reported a position in NVO in Q4 2024 and held it in 6 quarters. The position peaked at $17.8M in Q1 2025. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • PEAK6 reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
  • PEAK6 sold 156,695 Novo Nordisk shares in Q2 2026, an estimated $6.73M.
  • PEAK6 first reported a position in Novo Nordisk in Q4 2024 and held it in 6 quarters.
  • PEAK6's Novo Nordisk position peaked at $17.8M in Q1 2025.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on PEAK6's 13F filing for Q2 2026, filed 13 Aug 2026.